KLK3 and posterior cortical atrophy: However, previous randomized clinical trials and observational studies have shown limited benefit of radical treatment for men older than 65 years diagnosed with localized PCa.34,35 Furthermore, while we cannot draw direct conclusions regarding the association of baseline PSA level with PCa-specific mortality in this study, we believe men aged 55 to 60 years who undergo baseline PSA testing and do not develop clinically significant PCa after 13 years of follow-up are unlikely to experience PCa-specific mortality.